Results 161 to 170 of about 165,146 (288)

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

An interpretable machine learning model for predicting febrile seizures following enterovirus infection in children. [PDF]

Ann Med
Luo Y, Feng Y, Guo Y, Wang Y, Xia X, Feng Y.   +5 more
europepmc   +1 more source

Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta‐analysis

British Journal of Haematology, EarlyView.
Summary Anti‐cluster of differentiation 38 (Anti‐CD38) monoclonal antibodies such as daratumumab are widely used in multiple myeloma (MM), yet the timing and magnitude of infectious risk remain incompletely defined. We performed an individual patient‐level meta‐analysis of six randomized trials (N = 2989) comparing daratumumab‐ versus non‐daratumumab ...
Alissa Visram, Hira Mian, James Lee, Aaron Jones, Gregory R. Pond, Doris Hansen, Surbhi Sidana, Luciano J. Costa   +7 more
wiley   +1 more source

Integrated Multiomics Reveals Gut-Brain Axis Dysregulation and Phenotype-Specific Metabolic Signatures in Children with Febrile Seizures. [PDF]

Biomedicines
Zhang X, Ma L, Wen Y, Gao F, Xiao Y, Mao J.   +5 more
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Summary of Best Evidence for the Management and Recurrence Prevention of Febrile Seizures in Children. [PDF]

J Multidiscip Healthc
Tang R, Wang M, He X, He Q, Chen L, Liu D.   +5 more
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Metabolomic identification and analysis of potential biomarkers of febrile seizures. [PDF]

BMC Pediatr
Tang H, Yuan G, Li X, Pan S, Liang Y, Yang Q, Gao X.   +6 more
europepmc   +1 more source

Drug‐Refractory Dystonia: Benefits of Lamotrigine Therapy in a Case of SCN2A Epilepsy‐Dyskinesia Syndrome

Movement Disorders Clinical Practice, EarlyView.
Isobel S. Platt, Patrick B. Moloney, Sanjay M. Sisodiya, Thomas T. Warner   +3 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source